<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02931838</url>
  </required_header>
  <id_info>
    <org_study_id>IM011-011</org_study_id>
    <nct_id>NCT02931838</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study to evaluate efficacy and safety in subjects with moderate to severe Psoriasis treated&#xD;
      with BMS-986165&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 15, 2016</start_date>
  <completion_date type="Actual">November 16, 2017</completion_date>
  <primary_completion_date type="Actual">November 16, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage of Participants With Moderate to Severe Psoriasis Experiencing a 75% Improvement (Reduction From Baseline) in PASI Score (PASI-75 Response Rate) on Day 85 (Week 12)</measure>
    <time_frame>Day 1 to Day 85</time_frame>
    <description>Psoriasis Area and Severity Index (PASI) 75 response: patients who achieved ≥ 75% improvement (reduction) in PASI score compared to baseline were defined as PASI 75 responders. PASI scores can range from 0, corresponding to no signs of psoriasis up to theoretical maximum of 72.0, which means a higher PASI score reflects a higher psoriasis activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Day 1 to day 115</time_frame>
    <description>The safety and tolerability of BMS-986195 as assessed by the number of subjects with adverse events (AEs); number of subjects with serious adverse events (SAEs); number of subjects with adverse events leading to discontinuation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants on Day 85 With PASI-50, PASI-90, PASI-100.</measure>
    <time_frame>Day 1 to Day 85</time_frame>
    <description>Percentage of patients achieving Psoriasis Area and Severity Index (PASI) 50, PASI 90 and PASI 100 responses on Day 85. PASI 50 response: patients who achieved ≥ 50% improvement (reduction) in PASI score compared to baseline were defined as PASI 50 responders. PASI 90 response: patients who achieved ≥ 90% improvement (reduction) in PASI score compared to baseline were defined as PASI 90 responders. PASI 100 response: patients who achieved ≥ 100% improvement (reduction) in PASI score compared to baseline were defined as PASI 100 responders. PASI scores can range from 0, corresponding to no signs of psoriasis up to theoretical maximum of 72.0, which means a higher PASI score reflects a higher psoriasis activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants on Day 85 With sPGA Score of 0 or 1 (sPGA0/1 Response Rate).</measure>
    <time_frame>Day 1 to Day 85</time_frame>
    <description>Percentage of participants achieving a clear (0) or almost clear (1) status on the Static Physician Global Assessment (sPGA) on Day 85. This index evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The assessment was scored on a scale of 0 to 5, where 0 = clear, with no evidence of plaque elevation, erythema, or scale, and 5 = severe induration, erythema, and scaling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DLQI Scores on Day 85</measure>
    <time_frame>Day 1 to Day 85</time_frame>
    <description>The DLQI is a participant reported quality of life index which consists of 10 questions concerning symptoms and feelings, daily activities, leisure, work, school, personal relationships, and treatment during the last week. Each question is scored on a scale of 0 to 3 by a tick box: &quot;not at all&quot;, &quot;a little&quot;, &quot;a lot&quot;, or &quot;very much&quot;. The scores are summed, giving a range from 0 (no impairment of life quality) to 30 (maximum impairment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in BSA on Day 85</measure>
    <time_frame>Day 1 to Day 85</time_frame>
    <description>Measurement of psoriasis body surface area (BSA) involvement is estimated using the handprint method with the size of a patient's handprint representing ~1% of body surface area involved.The total BSA = 100% with breakdown by body region as follows: head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), trunk including axillae and groin = 30% (30 handprints), lower extremities including buttocks = 40% (40 handprints). A decrease from Baseline indicates improvement. Change from Baseline was calculated as Baseline score - Day 85 score; a positive change from Baseline therefore indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Observed Plasma Concentration of BMS-986165 (Ctrough)</measure>
    <time_frame>Days 8, 15, 29, 57, 85</time_frame>
    <description>Pharmacokinetics of BMS-986165 were derived from plasma concentration versus time data. Ctrough= Trough observed plasma concentration</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">268</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>BMS-986165 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specified dose of BMS-986165 on specified days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-986165 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specified dose of BMS-986165 on specified days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-986165 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specified dose of BMS-986165 on specified days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-986165 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specified dose of BMS-986165 on specified days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-986165 Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specified dose of BMS-986165 on specified days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Specified dose of Placebo for BMS-986165 on specified days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986165</intervention_name>
    <arm_group_label>BMS-986165 Dose 1</arm_group_label>
    <arm_group_label>BMS-986165 Dose 2</arm_group_label>
    <arm_group_label>BMS-986165 Dose 3</arm_group_label>
    <arm_group_label>BMS-986165 Dose 4</arm_group_label>
    <arm_group_label>BMS-986165 Dose 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for BMS-986165</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female, ages 18 to 70 years&#xD;
&#xD;
          -  Diagnosis of plaque psoriasis for 6 months&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy&#xD;
             test, must not be pregnant, lactating, breastfeeding or planning pregnancy&#xD;
&#xD;
          -  Males who are sexually active with WOCBP must agree to follow instructions for&#xD;
             method(s) of contraception for the duration of treatment plus 5 half-lives of the&#xD;
             study drug plus 90 days.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any significant acute or chronic medical illness&#xD;
&#xD;
          -  Blood transfusion within 4 weeks of study drug administration&#xD;
&#xD;
          -  Inability to tolerate oral medication&#xD;
&#xD;
          -  Positive hepatitis-B (HBV) surface antigen&#xD;
&#xD;
          -  Positive hepatitis-C (HCV) antibody&#xD;
&#xD;
          -  Any history or risk for tuberculosis (TB)&#xD;
&#xD;
          -  Any major illness/condition or evidence of an unstable clinical condition&#xD;
&#xD;
          -  Chest X-ray findings suspicious of infection at screening&#xD;
&#xD;
          -  has received ustekinumab, secukinumab or ixekizumab within 6 months of first&#xD;
             administration of study medication&#xD;
&#xD;
          -  Has received anti-Tumor Necrosis Factor (TNF) inhibitor(s) within 2 months of first&#xD;
             administration of study medication&#xD;
&#xD;
          -  Has received Rituximab within 6 months of first administration of study medication&#xD;
&#xD;
          -  Topical medications/treatments for psoriasis within 2 weeks of the first&#xD;
             administration of any study medication&#xD;
&#xD;
          -  Any systemic medications/treatments for psoriasis within 4 weeks of the first&#xD;
             administration of any study medication&#xD;
&#xD;
        Other protocol defined inclusion/exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologic Surgery Specialists, PC</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Christie Clinic, LLC</name>
      <address>
        <city>Champaign</city>
        <state>Illinois</state>
        <zip>61820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University Health System</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research Group, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center-Norris Cotton Cancer Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Plastic Surgery &amp; Dermatology - Charlotte/Blakeney Location</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Rocky Mount, LLC</name>
      <address>
        <city>Rocky Mount</city>
        <state>North Carolina</state>
        <zip>27804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington, PLC</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Sooner Research</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Concepts</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rivergate Dermatology Clinical Research Center, Pllc</name>
      <address>
        <city>Goodlettsville</city>
        <state>Tennessee</state>
        <zip>37072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Dermatology Associates</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2G 1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5K 1X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5H 1G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4W 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dresden</city>
        <zip>01097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hamburg</city>
        <zip>20253</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kiel</city>
        <zip>24103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Luebeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mahlow</city>
        <zip>15831</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Schwerin</city>
        <zip>19055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Stuttgart</city>
        <zip>70178</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>4678602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Fukuoka City</city>
        <state>Fukuoka</state>
        <zip>814-0180</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>6500017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kamigyo-ku</city>
        <state>Kyoto</state>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shimotsuke-shi</city>
        <state>Tochigi</state>
        <zip>3290498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>105-8471</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shinagawa-Ku</city>
        <state>Tokyo</state>
        <zip>141-8625</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Skinjuku-ku</city>
        <state>Tokyo</state>
        <zip>1690073</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kumamoto</city>
        <zip>8608556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Osaka</city>
        <zip>5500012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tokyo</city>
        <zip>1738606</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Daugavpils</city>
        <zip>LV-5404</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Riga</city>
        <zip>LV-1001</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Riga</city>
        <zip>LV-1003</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Riga</city>
        <zip>LV-1011</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Riga</city>
        <zip>LV-1013</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ventspils</city>
        <zip>LV3601</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zapopan</city>
        <state>Jalisco</state>
        <zip>45030</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Monterey</city>
        <state>Nuevo LEON</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Krakow</city>
        <zip>31-011</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lodz</city>
        <zip>90-436</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lublin</city>
        <zip>20-080</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Osielsko</city>
        <zip>86-031</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Siedlce</city>
        <zip>08 - 110</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Skierniewice</city>
        <zip>96-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Warszawa</city>
        <zip>00-660</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Warszawa</city>
        <zip>01-142</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Warszawa</city>
        <zip>01-817</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Warszawa</city>
        <zip>02-758</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Warszawa</city>
        <zip>02-777</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wroc?aw</city>
        <zip>51-318</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wroclaw</city>
        <zip>50368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Latvia</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 3, 2016</study_first_submitted>
  <study_first_submitted_qc>October 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2016</study_first_posted>
  <results_first_submitted>October 30, 2020</results_first_submitted>
  <results_first_submitted_qc>October 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 27, 2020</results_first_posted>
  <disposition_first_submitted>November 15, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>November 15, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 16, 2018</disposition_first_posted>
  <last_update_submitted>October 30, 2020</last_update_submitted>
  <last_update_submitted_qc>October 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BMS-986165</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 23, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT02931838/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 6, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT02931838/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>268 participants were randomized in the study; One participant was randomized but did not receive study drug due to being lost to follow-up</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo for BMS-986165</description>
        </group>
        <group group_id="P2">
          <title>BMS-986165 3MG QOD</title>
          <description>BMS-986165 3mg capsules Every Other Day</description>
        </group>
        <group group_id="P3">
          <title>BMS-986165 3MG QD</title>
          <description>BMS-986165 3mg capsules Every Day</description>
        </group>
        <group group_id="P4">
          <title>BMS-986165 3MG BID</title>
          <description>BMS-986165 3mg capsules Twice Daily</description>
        </group>
        <group group_id="P5">
          <title>BMS-986165 6MG BID</title>
          <description>BMS-986165 6mg capsules Twice Daily</description>
        </group>
        <group group_id="P6">
          <title>BMS-986165 12MG QD</title>
          <description>BMS-986165 12mg capsules Every Day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="45"/>
                <participants group_id="P5" count="45"/>
                <participants group_id="P6" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="42"/>
                <participants group_id="P5" count="39"/>
                <participants group_id="P6" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Reason not provided by investigator</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor/non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject request to discontinue treatment</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo for BMS-986165</description>
        </group>
        <group group_id="B2">
          <title>BMS-986165 3MG QOD</title>
          <description>BMS-986165 3mg capsules Every Other Day</description>
        </group>
        <group group_id="B3">
          <title>BMS-986165 3MG QD</title>
          <description>BMS-986165 3 mg capsules every day</description>
        </group>
        <group group_id="B4">
          <title>BMS-986165 3MG BID</title>
          <description>BMS-986165 3 mg capsules twice daily</description>
        </group>
        <group group_id="B5">
          <title>BMS-986165 6MG BID</title>
          <description>BMS-986165 6 mg capsules twice daily</description>
        </group>
        <group group_id="B6">
          <title>BMS-986165 12MG QD</title>
          <description>BMS-986165 12 mg capsules every day</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="44"/>
            <count group_id="B4" value="45"/>
            <count group_id="B5" value="45"/>
            <count group_id="B6" value="44"/>
            <count group_id="B7" value="267"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>All randomized and treated participants</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.4" spread="11.93"/>
                    <measurement group_id="B2" value="41.0" spread="11.8"/>
                    <measurement group_id="B3" value="45.0" spread="13.77"/>
                    <measurement group_id="B4" value="45.6" spread="15.10"/>
                    <measurement group_id="B5" value="42.8" spread="12.90"/>
                    <measurement group_id="B6" value="46.6" spread="11.62"/>
                    <measurement group_id="B7" value="44.6" spread="12.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>All randomized and treated participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="35"/>
                    <measurement group_id="B6" value="30"/>
                    <measurement group_id="B7" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>All randomized and treated participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="35"/>
                    <measurement group_id="B6" value="37"/>
                    <measurement group_id="B7" value="225"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Participants With Moderate to Severe Psoriasis Experiencing a 75% Improvement (Reduction From Baseline) in PASI Score (PASI-75 Response Rate) on Day 85 (Week 12)</title>
        <description>Psoriasis Area and Severity Index (PASI) 75 response: patients who achieved ≥ 75% improvement (reduction) in PASI score compared to baseline were defined as PASI 75 responders. PASI scores can range from 0, corresponding to no signs of psoriasis up to theoretical maximum of 72.0, which means a higher PASI score reflects a higher psoriasis activity.</description>
        <time_frame>Day 1 to Day 85</time_frame>
        <population>All Randomized and Treated Participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 3MG QOD</title>
            <description>BMS-986165 3mg capsules Every Other Day</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 3MG QD</title>
            <description>BMS-986165 3 mg capsules every day</description>
          </group>
          <group group_id="O4">
            <title>BMS-986165 3MG BID</title>
            <description>BMS-986165 3 mg capsules twice daily</description>
          </group>
          <group group_id="O5">
            <title>BMS-986165 6MG BID</title>
            <description>BMS-986165 6 mg capsules twice daily</description>
          </group>
          <group group_id="O6">
            <title>BMS-986165 12MG QD</title>
            <description>BMS-986165 12 mg capsules every day</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants With Moderate to Severe Psoriasis Experiencing a 75% Improvement (Reduction From Baseline) in PASI Score (PASI-75 Response Rate) on Day 85 (Week 12)</title>
          <description>Psoriasis Area and Severity Index (PASI) 75 response: patients who achieved ≥ 75% improvement (reduction) in PASI score compared to baseline were defined as PASI 75 responders. PASI scores can range from 0, corresponding to no signs of psoriasis up to theoretical maximum of 72.0, which means a higher PASI score reflects a higher psoriasis activity.</description>
          <population>All Randomized and Treated Participants</population>
          <units>Percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="1.4" upper_limit="18.3"/>
                    <measurement group_id="O2" value="9.1" lower_limit="2.5" upper_limit="21.7"/>
                    <measurement group_id="O3" value="38.6" lower_limit="24.4" upper_limit="54.5"/>
                    <measurement group_id="O4" value="68.9" lower_limit="53.4" upper_limit="81.8"/>
                    <measurement group_id="O5" value="66.7" lower_limit="51.0" upper_limit="80.0"/>
                    <measurement group_id="O6" value="75.0" lower_limit="59.7" upper_limit="86.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4873</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>P-value is from the Fishers Exact if at least one cell count is &lt;5. Otherwise, p-value is from the Chi-Square test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>P-value is from the Fishers Exact if at least one cell count is &lt;5. Otherwise, p-value is from the Chi-Square test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>P-value is from the Fishers Exact if at least one cell count is &lt;5. Otherwise, p-value is from the Chi-Square test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>P-value is from the Fishers Exact if at least one cell count is &lt;5. Otherwise, p-value is from the Chi-Square test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Nominal p-value</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>P-value is from the Fishers Exact if at least one cell count is &lt;5. Otherwise, p-value is from the Chi-Square test.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants on Day 85 With PASI-50, PASI-90, PASI-100.</title>
        <description>Percentage of patients achieving Psoriasis Area and Severity Index (PASI) 50, PASI 90 and PASI 100 responses on Day 85. PASI 50 response: patients who achieved ≥ 50% improvement (reduction) in PASI score compared to baseline were defined as PASI 50 responders. PASI 90 response: patients who achieved ≥ 90% improvement (reduction) in PASI score compared to baseline were defined as PASI 90 responders. PASI 100 response: patients who achieved ≥ 100% improvement (reduction) in PASI score compared to baseline were defined as PASI 100 responders. PASI scores can range from 0, corresponding to no signs of psoriasis up to theoretical maximum of 72.0, which means a higher PASI score reflects a higher psoriasis activity.</description>
        <time_frame>Day 1 to Day 85</time_frame>
        <population>All Randomized and Treated Participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 3MG QOD</title>
            <description>BMS-986165 3mg capsules Every Other Day</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 3MG QD</title>
            <description>BMS-986165 3 mg capsules every day</description>
          </group>
          <group group_id="O4">
            <title>BMS-986165 3MG BID</title>
            <description>BMS-986165 3 mg capsules twice daily</description>
          </group>
          <group group_id="O5">
            <title>BMS-986165 6MG BID</title>
            <description>BMS-986165 6 mg capsules twice daily</description>
          </group>
          <group group_id="O6">
            <title>BMS-986165 12MG QD</title>
            <description>BMS-986165 12 mg capsules every day</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants on Day 85 With PASI-50, PASI-90, PASI-100.</title>
          <description>Percentage of patients achieving Psoriasis Area and Severity Index (PASI) 50, PASI 90 and PASI 100 responses on Day 85. PASI 50 response: patients who achieved ≥ 50% improvement (reduction) in PASI score compared to baseline were defined as PASI 50 responders. PASI 90 response: patients who achieved ≥ 90% improvement (reduction) in PASI score compared to baseline were defined as PASI 90 responders. PASI 100 response: patients who achieved ≥ 100% improvement (reduction) in PASI score compared to baseline were defined as PASI 100 responders. PASI scores can range from 0, corresponding to no signs of psoriasis up to theoretical maximum of 72.0, which means a higher PASI score reflects a higher psoriasis activity.</description>
          <population>All Randomized and Treated Participants</population>
          <units>Percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% of participants with PASI-50 at Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1" lower_limit="18.2" upper_limit="46.6"/>
                    <measurement group_id="O2" value="43.2" lower_limit="28.3" upper_limit="59.0"/>
                    <measurement group_id="O3" value="68.2" lower_limit="52.4" upper_limit="81.4"/>
                    <measurement group_id="O4" value="91.1" lower_limit="78.8" upper_limit="97.5"/>
                    <measurement group_id="O5" value="77.8" lower_limit="62.9" upper_limit="88.8"/>
                    <measurement group_id="O6" value="88.6" lower_limit="75.4" upper_limit="96.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of participants with PASI-90 at Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="0.1" upper_limit="11.8"/>
                    <measurement group_id="O2" value="6.8" lower_limit="1.4" upper_limit="18.7"/>
                    <measurement group_id="O3" value="15.9" lower_limit="6.6" upper_limit="30.1"/>
                    <measurement group_id="O4" value="44.4" lower_limit="29.6" upper_limit="60.0"/>
                    <measurement group_id="O5" value="44.4" lower_limit="29.6" upper_limit="60.0"/>
                    <measurement group_id="O6" value="43.2" lower_limit="28.3" upper_limit="59.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of participants with PASI-100 at Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="7.9"/>
                    <measurement group_id="O2" value="2.3" lower_limit="0.1" upper_limit="12.0"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="8.9" lower_limit="2.5" upper_limit="21.2"/>
                    <measurement group_id="O5" value="17.8" lower_limit="8.0" upper_limit="32.1"/>
                    <measurement group_id="O6" value="25.0" lower_limit="13.2" upper_limit="40.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants on Day 85 With sPGA Score of 0 or 1 (sPGA0/1 Response Rate).</title>
        <description>Percentage of participants achieving a clear (0) or almost clear (1) status on the Static Physician Global Assessment (sPGA) on Day 85. This index evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The assessment was scored on a scale of 0 to 5, where 0 = clear, with no evidence of plaque elevation, erythema, or scale, and 5 = severe induration, erythema, and scaling.</description>
        <time_frame>Day 1 to Day 85</time_frame>
        <population>All Randomized and Treated Participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 3MG QOD</title>
            <description>BMS-986165 3mg capsules Every Other Day</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 3MG QD</title>
            <description>BMS-986165 3 mg capsules every day</description>
          </group>
          <group group_id="O4">
            <title>BMS-986165 3MG BID</title>
            <description>BMS-986165 3 mg capsules twice daily</description>
          </group>
          <group group_id="O5">
            <title>BMS-986165 6MG BID</title>
            <description>BMS-986165 6 mg capsules twice daily</description>
          </group>
          <group group_id="O6">
            <title>BMS-986165 12MG QD</title>
            <description>BMS-986165 12 mg capsules every day</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants on Day 85 With sPGA Score of 0 or 1 (sPGA0/1 Response Rate).</title>
          <description>Percentage of participants achieving a clear (0) or almost clear (1) status on the Static Physician Global Assessment (sPGA) on Day 85. This index evaluates the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The assessment was scored on a scale of 0 to 5, where 0 = clear, with no evidence of plaque elevation, erythema, or scale, and 5 = severe induration, erythema, and scaling.</description>
          <population>All Randomized and Treated Participants</population>
          <units>Percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="1.4" upper_limit="18.3"/>
                    <measurement group_id="O2" value="20.5" lower_limit="9.8" upper_limit="35.3"/>
                    <measurement group_id="O3" value="38.6" lower_limit="24.4" upper_limit="54.5"/>
                    <measurement group_id="O4" value="75.6" lower_limit="60.5" upper_limit="87.1"/>
                    <measurement group_id="O5" value="64.4" lower_limit="48.8" upper_limit="78.1"/>
                    <measurement group_id="O6" value="75.0" lower_limit="59.7" upper_limit="86.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DLQI Scores on Day 85</title>
        <description>The DLQI is a participant reported quality of life index which consists of 10 questions concerning symptoms and feelings, daily activities, leisure, work, school, personal relationships, and treatment during the last week. Each question is scored on a scale of 0 to 3 by a tick box: &quot;not at all&quot;, &quot;a little&quot;, &quot;a lot&quot;, or &quot;very much&quot;. The scores are summed, giving a range from 0 (no impairment of life quality) to 30 (maximum impairment)</description>
        <time_frame>Day 1 to Day 85</time_frame>
        <population>All Randomized and Treated Participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 3MG QOD</title>
            <description>BMS-986165 3mg capsules Every Other Day</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 3MG QD</title>
            <description>BMS-986165 3 mg capsules every day</description>
          </group>
          <group group_id="O4">
            <title>BMS-986165 3MG BID</title>
            <description>BMS-986165 3 mg capsules twice daily</description>
          </group>
          <group group_id="O5">
            <title>BMS-986165 6MG BID</title>
            <description>BMS-986165 6 mg capsules twice daily</description>
          </group>
          <group group_id="O6">
            <title>BMS-986165 12MG QD</title>
            <description>BMS-986165 12 mg capsules every day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DLQI Scores on Day 85</title>
          <description>The DLQI is a participant reported quality of life index which consists of 10 questions concerning symptoms and feelings, daily activities, leisure, work, school, personal relationships, and treatment during the last week. Each question is scored on a scale of 0 to 3 by a tick box: &quot;not at all&quot;, &quot;a little&quot;, &quot;a lot&quot;, or &quot;very much&quot;. The scores are summed, giving a range from 0 (no impairment of life quality) to 30 (maximum impairment)</description>
          <population>All Randomized and Treated Participants</population>
          <units>Score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.85" lower_limit="-4.33" upper_limit="-1.37"/>
                    <measurement group_id="O2" value="-3.76" lower_limit="-5.15" upper_limit="-2.38"/>
                    <measurement group_id="O3" value="-6.07" lower_limit="-8.07" upper_limit="-4.08"/>
                    <measurement group_id="O4" value="-9.67" lower_limit="-11.42" upper_limit="-7.93"/>
                    <measurement group_id="O5" value="-8.38" lower_limit="-10.72" upper_limit="-6.03"/>
                    <measurement group_id="O6" value="-10.16" lower_limit="-12.27" upper_limit="-8.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in BSA on Day 85</title>
        <description>Measurement of psoriasis body surface area (BSA) involvement is estimated using the handprint method with the size of a patient's handprint representing ~1% of body surface area involved.The total BSA = 100% with breakdown by body region as follows: head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), trunk including axillae and groin = 30% (30 handprints), lower extremities including buttocks = 40% (40 handprints). A decrease from Baseline indicates improvement. Change from Baseline was calculated as Baseline score - Day 85 score; a positive change from Baseline therefore indicates improvement.</description>
        <time_frame>Day 1 to Day 85</time_frame>
        <population>All Randomized and Treated Participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 3MG QOD</title>
            <description>BMS-986165 3mg capsules Every Other Day</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 3MG QD</title>
            <description>BMS-986165 3 mg capsules every day</description>
          </group>
          <group group_id="O4">
            <title>BMS-986165 3MG BID</title>
            <description>BMS-986165 3 mg capsules twice daily</description>
          </group>
          <group group_id="O5">
            <title>BMS-986165 6MG BID</title>
            <description>BMS-986165 6 mg capsules twice daily</description>
          </group>
          <group group_id="O6">
            <title>BMS-986165 12MG QD</title>
            <description>BMS-986165 12 mg capsules every day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in BSA on Day 85</title>
          <description>Measurement of psoriasis body surface area (BSA) involvement is estimated using the handprint method with the size of a patient's handprint representing ~1% of body surface area involved.The total BSA = 100% with breakdown by body region as follows: head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), trunk including axillae and groin = 30% (30 handprints), lower extremities including buttocks = 40% (40 handprints). A decrease from Baseline indicates improvement. Change from Baseline was calculated as Baseline score - Day 85 score; a positive change from Baseline therefore indicates improvement.</description>
          <population>All Randomized and Treated Participants</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.71" lower_limit="-11.88" upper_limit="-3.54"/>
                    <measurement group_id="O2" value="-5.50" lower_limit="-8.17" upper_limit="-2.83"/>
                    <measurement group_id="O3" value="-12.59" lower_limit="-18.28" upper_limit="-6.89"/>
                    <measurement group_id="O4" value="-18.60" lower_limit="-23.69" upper_limit="-13.52"/>
                    <measurement group_id="O5" value="-17.23" lower_limit="-20.85" upper_limit="-13.60"/>
                    <measurement group_id="O6" value="-15.16" lower_limit="-18.64" upper_limit="-11.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Observed Plasma Concentration of BMS-986165 (Ctrough)</title>
        <description>Pharmacokinetics of BMS-986165 were derived from plasma concentration versus time data. Ctrough= Trough observed plasma concentration</description>
        <time_frame>Days 8, 15, 29, 57, 85</time_frame>
        <population>All participants who received any study medication and have any available concentration-time data.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS-986165 3MG QOD</title>
            <description>BMS-986165 3mg capsules Every Other Day</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 3MG QD</title>
            <description>BMS-986165 3 mg capsules every day</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 3MG BID</title>
            <description>BMS-986165 3 mg capsules twice daily</description>
          </group>
          <group group_id="O4">
            <title>BMS-986165 6MG BID</title>
            <description>BMS-986165 6 mg capsules twice daily</description>
          </group>
          <group group_id="O5">
            <title>BMS-986165 12MG QD</title>
            <description>BMS-986165 12 mg capsules every day</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Observed Plasma Concentration of BMS-986165 (Ctrough)</title>
          <description>Pharmacokinetics of BMS-986165 were derived from plasma concentration versus time data. Ctrough= Trough observed plasma concentration</description>
          <population>All participants who received any study medication and have any available concentration-time data.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.024" spread="3.7061"/>
                    <measurement group_id="O2" value="3.145" spread="3.1588"/>
                    <measurement group_id="O3" value="14.819" spread="9.1410"/>
                    <measurement group_id="O4" value="26.257" spread="14.6483"/>
                    <measurement group_id="O5" value="17.824" spread="22.7536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>The safety and tolerability of BMS-986195 as assessed by the number of subjects with adverse events (AEs); number of subjects with serious adverse events (SAEs); number of subjects with adverse events leading to discontinuation</description>
        <time_frame>Day 1 to day 115</time_frame>
        <population>All Randomized and Treated Participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 3MG QOD</title>
            <description>BMS-986165 3mg capsules Every Other Day</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 3MG QD</title>
            <description>BMS-986165 3 mg capsules every day</description>
          </group>
          <group group_id="O4">
            <title>BMS-986165 3MG BID</title>
            <description>BMS-986165 3 mg capsules twice daily</description>
          </group>
          <group group_id="O5">
            <title>BMS-986165 6MG BID</title>
            <description>BMS-986165 6 mg capsules twice daily</description>
          </group>
          <group group_id="O6">
            <title>BMS-986165 12MG QD</title>
            <description>BMS-986165 12 mg capsules every day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>The safety and tolerability of BMS-986195 as assessed by the number of subjects with adverse events (AEs); number of subjects with serious adverse events (SAEs); number of subjects with adverse events leading to discontinuation</description>
          <population>All Randomized and Treated Participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No. of participants with SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. of participants with AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="36"/>
                    <measurement group_id="O6" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. of participants discontinued due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>20 weeks (assessed up to November 16, 2017)</time_frame>
      <desc>All Serious Adverse Events were collected from the date of participant's written consent until 30 days post discontinuation of dosing or participant's participation in the study if the last scheduled visit occurs at a later time. The collection of non-serious Adverse Event information began at initiation of study drug.Treatment Emergent AEs are determined from first dose to within 30 days after last dose.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo for BMS-986165</description>
        </group>
        <group group_id="E2">
          <title>BMS-986165 3mg QOD</title>
          <description>BMS-986165 3mg capsules Every Other Day</description>
        </group>
        <group group_id="E3">
          <title>BMS-986165 3mg QD</title>
          <description>BMS-986165 3 mg capsules every day</description>
        </group>
        <group group_id="E4">
          <title>BMS-986165 3mg BID</title>
          <description>BMS-986165 3 mg capsules twice daily</description>
        </group>
        <group group_id="E5">
          <title>BMS-986165 6mg BID</title>
          <description>BMS-986165 6 mg capsules twice daily</description>
        </group>
        <group group_id="E6">
          <title>BMS-986165 12mg QD</title>
          <description>BMS-986165 12 mg capsules every day</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Blood immunoglobulin e increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The limitations of this phase 2 trial include its small sample size and short duration; these results warrant confirmation in a larger trial of longer duration</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <phone>Please email</phone>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

